Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells

Jeremy D Grevet,Xianjiang Lan,Nicole Hamagami,Christopher R Edwards,Laavanya Sankaranarayanan,Xinjun Ji,Saurabh K Bhardwaj,Carolyne J Face,David F Posocco,Osheiza Abdulmalik,Cheryl A Keller,Belinda Giardine,Simone Sidoli,Ben A Garcia,Stella T Chou,Stephen A Liebhaber,Ross C Hardison,Junwei Shi,Gerd A Blobel,Jeremy D. Grevet,Christopher R. Edwards,Saurabh K. Bhardwaj,Carolyne J. Face,David F. Posocco,Cheryl A. Keller,Ben A. Garcia,Stella T. Chou,Stephen A. Liebhaber,Ross C. Hardison,Gerd A. Blobel

DOI: https://doi.org/10.1126/science.aao0932

IF: 56.9

2018-07-20

Science

Abstract:A CRISPR screen for RBC regulators Hemoglobin in red blood cells (RBCs) carries oxygen to the tissues. Sickle cell disease is an inherited condition that involves abnormal hemoglobin. Current treatments entail modulating the level of fetal hemoglobin expression. Grevet et al. performed a CRISPR-Cas9 screen for regulators of fetal hemoglobin in RBCs and identified heme-regulated eIF2α kinase (HRI). Depleting the kinase in RBCs led to an increase in fetal hemoglobin levels and reduced sickling of cultured human RBCs. Thus, HRI may be a therapeutic target for sickle cell disease and other hemoglobin disorders. Science , this issue p. 285

multidisciplinary sciences